In 2021, the IQ Consortium continued to advance key initiatives across the pharmaceutical industry while focusing on delivering innovative medicines to address COVID-19 and its variants. The consortium has grown to more than 2300 participants engaged in activities across 10 leadership groups and 100+ working groups. IQ’s portfolio remains robust; our membership developed several impactful publications and presentations and continued to engage with global regulatory authorities. Read the IQ Annual Report 2021 to learn more.